These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19114568)

  • 1. Impact of substance disorders on medical expenditures for medicaid beneficiaries with behavioral health disorders.
    Clark RE; Samnaliev M; McGovern MP
    Psychiatr Serv; 2009 Jan; 60(1):35-42. PubMed ID: 19114568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicaid Expenditures for Fee-for-Service Enrollees with Behavioral Diagnoses: Findings from a 50 State Claims Analysis.
    Ward MC; Lally C; Druss BG
    Community Ment Health J; 2017 Jan; 53(1):1-7. PubMed ID: 27306989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk adjustment alternatives in paying for behavioral health care under Medicaid.
    Ettner SL; Frank RG; McGuire TG; Hermann RC
    Health Serv Res; 2001 Aug; 36(4):793-811. PubMed ID: 11508640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth in Spending on and Use of Services for Mental and Substance Use Disorders After the Great Recession Among Individuals With Private Insurance.
    Mark TL; Hodgkin D; Levit KR; Thomas CP
    Psychiatr Serv; 2016 May; 67(5):504-9. PubMed ID: 26725293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of substance abuse treatment on Medicaid expenditures among general assistance welfare clients in Washington state.
    Wickizer TM; Krupski A; Stark KD; Mancuso D; Campbell K
    Milbank Q; 2006; 84(3):555-76. PubMed ID: 16953810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of psychiatric disorders and costs of care among adult enrollees in a Medicaid HMO.
    Thomas MR; Waxmonsky JA; Gabow PA; Flanders-McGinnis G; Socherman R; Rost K
    Psychiatr Serv; 2005 Nov; 56(11):1394-401. PubMed ID: 16282258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment for co-occurring mental and substance use disorders in five state Medicaid programs.
    Clark RE; Samnaliev M; McGovern MP
    Psychiatr Serv; 2007 Jul; 58(7):942-8. PubMed ID: 17602010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of eliminating behavioral health benefits for selected medicaid enrollees.
    McConnell KJ; Wallace NT; Gallia CA; Smith JA
    Health Serv Res; 2008 Aug; 43(4):1348-65. PubMed ID: 18384360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).
    Rothbard AB; Lee S; Blank MB
    J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The implementation of managed behavioral healthcare in Colorado and the effects on older Medicaid beneficiaries.
    Kaskie B; Wallace N; Kang S; Bloom J
    J Ment Health Policy Econ; 2006 Mar; 9(1):15-24. PubMed ID: 16733268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicaid expenditures on behavioral health care.
    Mark TL; Buck JA; Dilonardo JD; Coffey RM; Chalk M
    Psychiatr Serv; 2003 Feb; 54(2):188-94. PubMed ID: 12556599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral disorders and diabetes-related outcomes among Massachusetts Medicare and Medicaid beneficiaries.
    Leung G; Zhang J; Lin WC; Clark RE
    Psychiatr Serv; 2011 Jun; 62(6):659-65. PubMed ID: 21632736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Medical Homes on Expenditures and Utilization for Beneficiaries With Behavioral Health Conditions.
    Romaire MA; Keyes V; Parish WJ; Kim K
    Psychiatr Serv; 2018 Aug; 69(8):871-878. PubMed ID: 29759058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decomposing Medicaid Spending During Health System Reform and ACA Expansion: Evidence From Oregon.
    Renfro S; Lindner S; McConnell KJ
    Med Care; 2018 Jul; 56(7):589-595. PubMed ID: 29762274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of copayments with healthcare utilization and expenditures among Medicaid enrollees with a substance use disorder.
    Lazic A; Tilford JM; Davis VP; Brown CC
    J Subst Use Addict Treat; 2024 Jun; 161():209314. PubMed ID: 38369244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mental health spending by private insurance: implications for the mental health parity and addiction equity act.
    Mark TL; Vandivort-Warren R; Miller K
    Psychiatr Serv; 2012 Apr; 63(4):313-8. PubMed ID: 22476300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care.
    Dickey B; Azeni H
    Am J Public Health; 1996 Jul; 86(7):973-7. PubMed ID: 8669521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychotropic drug use and expenditures among medicaid beneficiaries with and without other mental health or substance abuse services.
    Hennessy KD; Green-Hennessy S; Buck JA; Miller K
    J Nerv Ment Dis; 2003 Jul; 191(7):476-8. PubMed ID: 12891096
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of Medicaid disease management programs on medical expenditures: Evidence from a natural experiment in Georgia.
    Kranker K
    J Health Econ; 2016 Mar; 46():52-69. PubMed ID: 26851876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do adjusted clinical groups eliminate incentives for HMOs to avoid substance abusers? Evidence from the Maryland Medicaid HealthChoice program.
    Ettner SL; Johnson S
    J Behav Health Serv Res; 2003; 30(1):63-77. PubMed ID: 12633004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.